ERBB2 and breast carcinoma: To verify whether ezetimibe has a specific effect on triple‐negative breast cancer, we also assessed its inhibitory effect on metastasis in the luminal A (MCF7) and HER2‐enriched (MDA‐MB‐453) breast cancer cell lines in Fig. S2c,d.